Straits Times Index
3,377.65 +11.98 (+0.36%) S&P 500
4,119.21 +42.61 (+1.05%) Dow
34,092.96 +6.92 (+0.02%) Nasdaq
11,816.32 +231.77 (+2.00%) BTC-USD
23,712.98 +539.66 (+2.33%) CMC Crypto 200
538.70 +296.03 (+121.98%)
Kronos Bio, Inc. (KRON)
After hours:
| Previous close | 2.4000 |
| Open | 2.4200 |
| Bid | 2.3700 x 1000 |
| Ask | 2.3900 x 800 |
| Day's range | 2.2800 - 2.5000 |
| 52-week range | 1.3500 - 9.0750 |
| Volume | |
| Avg. volume | 279,870 |
| Market cap | 134.28M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9230 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- Zacks
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- CNW Group
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute
